.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Poster

eP167

A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma

Presented in

Selbststudium: Non Melanoma Skin Cancer: PEK und BCC

Authors

John Kaczmar (North Charleston, SC, US), Kyriakos P. Papadopoulos (San Antonio, TX, US), George Ansstas (St. Louis, MO, US), Ariel Birnbaum (Providence, RI, US), Janice Mehnert (New Brunswick, NJ, US), Omid Hamid (Los Angeles, CA, US), Brett G.M. Hughes (Brisbane, AU), Guilherme Rabinowits (Miami, FL, US), Alexander Z. Wei (New York, NY, US), Melinda Yushak (Atlanta, GA, US), Jayakumar Mani (Tarrytown, NY, US), Fang Fang (Tarrytown, NY, US), JuAn Wang (Tarrytown, NY, US), Glenn Kroog (Tarrytown, NY, US), Mark Salvati (Tarrytown, NY, US), Israel Lowy (Tarrytown, NY, US), Matthew G. Fury (Tarrytown, NY, US)